Literature DB >> 16508757

When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).

Christian J Wiedermann.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16508757     DOI： 10.1007/s00134-006-0086-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  6 in total

1.  Activated protein C: do more survive?

Authors:  Alasdair F Mackenzie
Journal:  Intensive Care Med       Date:  2005-10-15       Impact factor: 17.440

2.  Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Authors:  Peter Q Eichacker; Robert L Danner; Anthony F Suffredini; Xizhong Cui; Charles Natanson
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

3.  Bioethics, the Surviving Sepsis Campaign, and the industry.

Authors:  Christian J Wiedermann
Journal:  Wien Klin Wochenschr       Date:  2005-07       Impact factor: 1.704

4.  Drotrecogin alfa (activated) in severe sepsis.

Authors:  Jan O Friedrich
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

5.  Cash interests taint drug advice.

Authors:  Rosie Taylor; Jim Giles
Journal:  Nature       Date:  2005-10-20       Impact factor: 49.962

6.  A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.

Authors:  Christian J Wiedermann; Nicole C Kaneider
Journal:  BMC Emerg Med       Date:  2005-10-14
  6 in total
  8 in total

1.  The European Society of Intensive Care Medicine (ESICM) and the Surviving Sepsis Campaign (SSC).

Authors:  V Marco Ranieri; Rui P Moreno; Andy Rhodes
Journal:  Intensive Care Med       Date:  2007-02-16       Impact factor: 17.440

2.  [Endogenous anticoagulant therapy for sepsis. Success and failure].

Authors:  C J Wiedermann
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743

3.  How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  Intensive Care Med       Date:  2008-05-27       Impact factor: 17.440

4.  The effects of sepsis on endothelium and clinical implications.

Authors:  Elena V Dolmatova; Keke Wang; Rohan Mandavilli; Kathy K Griendling
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

5.  Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis.

Authors:  Vania Costa; James M Brophy
Journal:  BMC Anesthesiol       Date:  2007-06-25       Impact factor: 2.217

6.  Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

7.  Activated protein C: cost-effective or costly?

Authors:  Savtaj Singh Brar; Braden J Manns
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

8.  Cost-effectiveness of activated protein C in real-life clinical practice.

Authors:  Jean-François Dhainaut; Stéphanie Payet; Benoit Vallet; Lionel Riou França; Djillali Annane; Pierre-Edouard Bollaert; Yves Le Tulzo; Isabelle Runge; Yannick Malledant; Bertrand Guidet; Katell Le Lay; Robert Launois
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.